Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2013 | Review Article

Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours

Authors: Christophe Van de Wiele, Vibeke Kruse, Peter Smeets, Mike Sathekge, Alex Maes

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2013

Abstract

Data available in patients suffering from squamous cell carcinoma of the head and neck, lung carcinoma, oesophageal carcinoma and gynaecological malignancies suggest that metabolic tumour volume and to a lesser extent total lesion glycolysis have the potential to become valuable in the imaging of human solid tumours as prognostic biomarkers for short- to intermediate-term survival outcomes, adding value to clinical staging, for assessment of response to treatment with neoadjuvant and concurrent chemotherapy, and for treatment optimization; for example, based on early treatment response assessment using changes in metabolic tumour volume over time, it might be possible to select patients who require a more aggressive treatment to improve their outcome. Prospective studies enrolling consecutive patients, adopting standardized protocols for FDG PET acquisition and processing, adjusting for potential confounders in the analysis (tumour size and origin) and determining the optimal methodology for determination of these novel markers are mandatory.

Murchison JT. TNM staging update for lung cancer: why is this important? World J Radiol. 2012;4:126–7.PubMedCrossRef

Ball DL, Fisher R, Burmeister B, Graham P, Joseph D, Penniment M, et al. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol. 2006;1:667–72.PubMedCrossRef

Doweck I, Denys D, Robbins KT. Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. Laryngoscope. 2002;112:1742–9.PubMedCrossRef

Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A, Ciuleanou E, Ghilezan N, et al. Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys. 2004;59:1018–26.PubMedCrossRef

Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, et al. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med. 2010;51:1870–7.PubMedCrossRef

Cheebsumon P, van Velden FH, Yaqub M, Hoekstra CJ, Velasquez LM, Hayes W, Hoekstra OS, et al. Measurement of metabolic tumor volume: static versus dynamic FDG scans. EJNMMI Res. 2011;1:35.PubMedCrossRef

American Cancer Society. Cancer Facts and Figures. www.cancer.org/Research/CancerFactsFigures/Index. Accessed 2 Nov 2012.

van der Schroeff MP, Baatenburg de Jong RJ. Staging and prognosis in head and neck cancer. Oral Oncol. 2009;45:356–60.PubMedCrossRef

Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:1085–93.PubMedCrossRef

10.

Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083–95.PubMedCrossRef

11.

Chung MK, Jeong HS, Son YI, So YK, Park GY, Choi JY, et al. Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Ann Surg Oncol. 2009;16:3111–7.PubMedCrossRef

12.

Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709–15.PubMedCrossRef

13.

Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of (18)F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck. 2012. doi:10.1002/hed.22904.

14.

Chan SC, Chang JT, Lin CY, Ng SH, Wang HM, Liao CT, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun. 2011;32:989–96.PubMedCrossRef

15.

Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2010;136:883–9.PubMedCrossRef

16.

Kao CH, Lin SC, Hsieh TC, Yen KY, Yang SN, Wang YC, et al. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1297–305.PubMedCrossRef

17.

Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861–8.PubMedCrossRef

18.

La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335–41.PubMedCrossRef

19.

Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83:1514–20.PubMedCrossRef

20.

Deron P, Mertens K, Goethals I, Rottey S, Duprez F, De Neve W, et al. Metabolic tumour volume. Prognostic value in locally advanced squamous cell carcinoma of the head and neck. Nuklearmedizin. 2011;50:141–6.PubMedCrossRef

21.

Murphy JD, La TH, Chu K, Quon A, Fischbein NJ, Maxim PG, et al. Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;80:514–21.PubMedCrossRef

22.

Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol. 2010;49:201–8.PubMedCrossRef

23.

Romesser PB, Qureshi MM, Shah BA, Chatburn LT, Jalisi S, Devaiah AK, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med. 2012;26:527–34.PubMedCrossRef

24.

Mountain CF. A new international staging system for lung cancer. 1986. Chest. 2009;136(5 Suppl):e25.PubMed

25.

Cogen A, Dockx Y, Cheung K, Meulemans E, Lauwers P, Nia P, et al. TNM-classification for lung cancer: from the 7th to the 8th edition. Acta Chir Belg. 2011;111:389–92.PubMed

26.

Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57.PubMedCrossRef

27.

Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28:173–85.PubMedCrossRef

28.

de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654–64.PubMedCrossRef

29.

Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328–33.PubMedCrossRef

30.

Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le QT, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer. 2012;13:52–8.PubMedCrossRef

31.

Yan H, Wang R, Zhao F, Zhu K, Jiang S, Zhao W, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Acta Radiol. 2011;52:646–50.PubMedCrossRef

32.

Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012;19:69–77.PubMedCrossRef

33.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27–38.PubMedCrossRef

34.

Zhang H, Wroblewski K, Appelbaum D, Pu Y. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer. Int J Comput Assist Radiol Surg. 2012. doi:10.1007/s11548-012-0749-7.

35.

Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33:613–20.PubMedCrossRef

36.

Meng X, Sun X, Mu D, Xing L, Ma L, Zhang B, et al. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;82:960–6.PubMedCrossRef

37.

Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628–35.PubMedCrossRef

38.

Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73:332–7.PubMedCrossRef

39.

Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:925–35.PubMedCrossRef

40.

van Loon J, Offermann C, Ollers M, van Elmpt W, Vegt E, Rahmy A, et al. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother Oncol. 2011;99:172–5.PubMedCrossRef

41.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef

42.

Pennathur A, Luketich J. Resection of esophageal cancer: strategies for optimal management. Ann Thorac Surg. 2008;85:751–6.CrossRef

43.

Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D. An audit of the treatment of cancer of the oesophagus. Gut. 1994;35:941–5.PubMedCrossRef

44.

Lordick F, Ott K, Sendler A. Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy. Chirurg. 2011;82:968–73.PubMedCrossRef

45.

Zhu W, Xing L, Yue J, Sun X, Sun X, Zhao H, et al. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. Br J Radiol. 2012;85:e694–701.PubMedCrossRef

46.

Downey RJ, Akhurst T, Ilson D, Ginsburg R, Bains M, Gonen M, et al. Whole body 18FDG PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428–32.PubMedCrossRef

47.

Flamen P, Van Cutsem E, Lerut A, Cambier J, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361–8.PubMedCrossRef

48.

Javeri H, Xiao L, Rohren E, Lee J, Liao Z, Hofstetter W, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184–92.PubMedCrossRef

49.

Levine E, Farmer M, Clark P, Mishra G, Ho C, Geisinger K, et al. Predictive value of 18-fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472–8.PubMedCrossRef

50.

Swisher S, Erasmus J, Maish M, Correa A, Macapinlac H, Ajani J, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776–85.PubMedCrossRef

51.

Vallbohmer D, Holscher A, Dietlein M, Bollschweiler E, Baldus S, Mönig S, et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888–94.PubMedCrossRef

52.

Kim M, Ryu J, Kim S, Ahn J, Kim S, Park S, et al. Value of complete metabolic response by 18F-fluorodeoxyglucose-psoitron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer. 2007;43:1385–91.PubMedCrossRef

53.

Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797–805.PubMedCrossRef

54.

Zhong X, Yu J, Zhang B, Mu D, Zhang W, Li D, et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;73:136–41.PubMedCrossRef

55.

Mamede M, El Fakhri G, Abreu-e-Lima P, Gandler W, Nosé V, Gerbaudo VH. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med. 2007;21:553–62.PubMedCrossRef

56.

Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, et al. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg. 2008;86:1131–8.PubMedCrossRef

57.

I HS, Kim SJ, Kim IJ, Kim K. Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer. Clin Nucl Med. 2012;37:442–6.PubMedCrossRef

58.

Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115–22.PubMedCrossRef

59.

Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol. 2007;30:377–88.PubMedCrossRef

60.

Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:471–7.PubMedCrossRef

61.

Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89:278–86.PubMedCrossRef

62.

Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872–80.PubMedCrossRef

63.

Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res. 2008;14:5236–41.PubMedCrossRef

64.

Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738–44.PubMedCrossRef

65.

Kidd EA, Thomas M, Siegel BA, Dehdashti F, Grigsby PW. Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys. 2012. doi:10.1016/j.ijrobp.2012.02.056.

66.

Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270–4.PubMedCrossRef

67.

Sharma DN, Rath GK, Kumar R, Malhotra A, Kumar S, Pandjatcharam J, et al. Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy. J Cancer Res Ther. 2012;8:23–7.PubMedCrossRef

68.

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505.PubMedCrossRef

69.

Liu FY, Chao A, Lai CH, Chou HH, Yen TC. Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol. 2012;125:566–71.PubMedCrossRef

70.

Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1966–72.PubMedCrossRef

71.

Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med. 2009;23:349–54.PubMedCrossRef

72.

Tann M, Sandrasegaran K, Jennings S, Skandarajah A, McHenry L, Schmidt C. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin Radiol. 2007;62:745–51.PubMedCrossRef

73.

Orlacchio A, Schillaci O, Antonelli L, D’Urso S, Sergiacomi G, Nicoli P, Simonetti G. Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT. Radiol Med. 2007;112:157–73.PubMedCrossRef

74.

Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg. 2005;79:948–88.CrossRef

75.

Kang W, Chung J, So Y, Jeong J, Lee D, Lee M. Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours. Eur J Nucl Med Mol Imaging. 2004;31:202–7.PubMedCrossRef

76.

Nakamoto Y, Higashi T, Sakahara H, Ishimori T, Kobayahsi H, Ishizu K, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547–54.PubMedCrossRef

77.

Erdi Y, Mawlawi O, Larson S, Imbriaco M, Yeung H, Finn R, Humm J. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;15:2505–20509.CrossRef

78.

Zasadny K, Kison P, Francis R, Wahl R. FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Positron Imaging. 1998;1:123–9.PubMedCrossRef

79.

Murphy JD, Chisholm KM, Daly ME, Wiegner EA, Truong D, Iagaru A, et al. Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. Radiother Oncol. 2011;101:356–61.PubMedCrossRef

80.

Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med. 2006;47:1808–12.PubMed

81.

Minn H, Clavo AC, Grénman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252–8.PubMed

82.

Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol. 1996;23:941–6.PubMedCrossRef

Title: Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours
Authors: Christophe Van de Wiele
Vibeke Kruse
Peter Smeets
Mike Sathekge
Alex Maes
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2280-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Dosimetry of 223Ra-chloride: dose to normal organs and tissues

1,25-Dihydroxy vitamin D and coronary microvascular function

Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT

Feasibility of perfusion CT technique integrated into conventional 18FDG/PET-CT studies in lung cancer patients: clinical staging and functional information in a single study

Should HIV-infected patients be screened for silent myocardial ischaemia using gated myocardial perfusion SPECT?

Evaluation in vitro and in animals of a new 11C-labeled PET radioligand for metabotropic glutamate receptors 1 in brain